GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...

After five years away, Joshua Gunn returns to Durham to spearhead the next wave of economic success in his hometown.

“We've absolutely killed Labour,” a senior Reform source told PoliticsHome, adding: “The more they sing our tune, the more we ... North Norhamptonshire, Durham and West Northamptonshire.

In another deal that highlights the pressures facing companies in the digital health sector, Akili Interactive has agreed to go private in a merger with Virtual Therapeutics. The announcement ...

PMGC Capital has acquired 83,500 shares of Alaunos Therapeutics, representing approximately 5.09% of the company’s outstanding ...

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United ...

North Carolina-based biotech Tune Therapeutics has raised $175 million in a Series B that will help it to take its lead epigenetic silencing drug, Tune-401, into clinical testing as a potential ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated ...

Angela Edwardson, Chief People Officer, Novotech Novotech was recognized in the Research and Development category for its innovative partnership with Tune Therapeutics, a leader in epigenome editing.

The spinout, dubbed Antares Therapeutics, will be guided by the Scorpion leadership team, with former Scorpion CEO Adam Friedman, M.D., Ph.D., at the helm. The new biotech’s portfolio includes ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated ...